Adicon Extends Deadline for Crown Bioscience Acquisition to November
MT Newswires Live
Yesterday
Adicon (HKG:9860) extended the deadline for regulatory approvals for its proposed acquisition of 100% of Crown Bioscience International to Nov. 13 from Aug. 13, according to a Wednesday Hong Kong bourse filing.
The deadline was automatically extended by three months because the required approvals had not been obtained by the original deadline.
Adicon's wholly owned unit Miramar Lifesciences agreed in November 2025 to acquire Crown Bioscience for up to $204 million. The acquisition remains subject to regulatory approvals required under the share purchase agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.